Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Worldwide sales of naproxen and naproxen sodium increased 5% during the fiscal 1985 third quarter to $99.9 mil., Syntex announced May 23 in results for the period ended April 30. Announcing the results, Chairman Albert Bowers, PhD, said "demand for naproxen and naproxen sodium, Syntex' major pharmaceutical product line, remains strong." Sales of the NSAID line were up 11% in the U.S. during the quarter to $67.9 mil. Worldwide sales through nine months for naproxen/naproxen sodium topped $300 mil. Overall corporate sales for the quarter were down 3.8%, to $227 mil., from last year's third quarter sales of $235.9 mil. Sales for the nine months were up 1.2% to $692.7 mil. Net earnings for the quarter were up 8.6% to $37.1 mil. However, nine months earnings were off 1.7% from last year to $106 mil., the company reported. Syntex' U.S. pharmaceutical volume increase 3% in the quarter to $105.9 mil.; however, an 8% decline in foreign Rx sales to $59.9 mil. kept worldwide volume relatively static. Worldwide Rx sales dipped 1.2% to $162.8 mil. Commenting on the pharmaceutical segment's performance, Bowers said: "We are pleased that our pharmaceutical products continued to display good profitability during the third quarter." Bowers added that the firm's 3 percentage point increase in gross margin as a percent of sales was largely due to "strong margins in the pharmaceuticals business and improved performance in the diagnostics division." The company's diagnostic product sales were relatively steady with a 1% increase to $22.3 mil. for the quarter. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts